CEMIP2

Across TCGA pan-cancer cohorts, CEMIP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEMIP2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CEMIP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEMIP2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where CEMIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.193	0.731	<.001	53	view →
LUAD	OS	Median	II,III,IV	0.429	0.911	.008	17	view →
GBM	OS	Quartile	All	0.405	0.744	.007	8	view →
COAD	DFS	Median	All	1.000	0.904	.042	6	view →
PDAC	OS	Median	III,IV	0.389	0.788	.026	4	view →
LSCC	OS	Median	III,IV	1.000	0.733	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEMIP2–CCRCC (DFS)

Open the CCRCC breakdown →